Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.95T
Revenue (ttm)	1.44T
Net Income (ttm)	38.48B
Shares Out	11.51M
EPS (ttm)	3,344.47
PE Ratio	50.56
Forward PE	16.34
Dividend	600.00 (0.36%)
Ex-Dividend Date	Dec 27, 2024

Volume	31,427
Average Volume	40,154
Open	166,000
Previous Close	164,400
Day's Range	165,200 - 174,500
52-Week Range	107,000 - 173,000
Beta	0.42
RSI	67.11
Earnings Date	Aug 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.